Table 1 Clinical features of study participants
Male sex, n (%) | 134 (93.1 %) |
Age, mean (SD) | 59 (12) years |
Ethnicity, n (%) | |
Māori Pacific Non-Māori, non-Pacific | 16 (11.0 %) 63 (43.8 %) 65 (45.1 %) |
Disease duration, mean (SD) | 22 (12) years |
Number of tophi, median (range) | 4.5 (1–41) |
Urate-lowering therapy use, n (%) | |
None Allopurinol Probenecid Benzbromarone Combination of allopurinol plus uricosuric | 4 (2.7 %) 126 (87.5 %) 4 (2.7 %) 3 (2.1 %) 7 (4.9 %) |
Serum urate, mean (SD) | 0.40 (0.12) mmol/L |